title: Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT.
abstract: Immunotherapy using subcutaneous injections of recombinant interleukin-2 (IL-2) and recombinant interferon alpha-2a (IFN-alpha) for advanced hematologic and solid tumors is rapidly developing. We report five patients with Hodgkin's and non-Hodgkin's lymphoma who developed a local cutaneous reaction consisting of inflammatory painful nodules with a central multiloculated vesicle at the site of sc injections of IL-2 and IFN-alpha immunotherapy following ABMT. This is the first report of a local cutaneous adverse reaction induced by IL-2 and IFN-alpha immunotherapy following ABMT.
authors.affiliation: Department of Dermatology, Hadassah University Hospital, Jerusalem, Israel.
authors.forename: L
authors.initials: L
authors.lastname: Klapholz
authors.forename: A
authors.initials: A
authors.lastname: Ackerstein
authors.forename: M A
authors.initials: MA
authors.lastname: Goldenhersh
authors.forename: D
authors.initials: D
authors.lastname: Vardy
authors.forename: A
authors.initials: A
authors.lastname: Nagler
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D004893:Erythema Nodosum / Q000209:etiology* / Q000473:pathology; D005260:Female; D006689:Hodgkin Disease / Q000601:surgery / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects*; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery / Q000628:therapy*; D008297:Male; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins